Finance

Lists
GUD:TSE
Knight Therapeutics Inc
CA$12.06
+0.08%
(+0.010) 1D
Nov 13, 4:00:00 PM GMT-5  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for GUD...
Open
CA$12.10
High
CA$12.18
Low
CA$11.89
Mkt. cap
1.19B
Avg. vol.
70.30K
Volume
45.58K
P/E ratio
75.03
52-wk high
CA$12.18
52-wk low
CA$5.66
EPS
CA$0.16
Beta
-0.05
Shares outstanding
98.23M
No. of employees
830
Open
CA$12.10
High
CA$12.18
Low
CA$11.89
Mkt. cap
1.19B
Avg. vol.
70.30K
Volume
45.58K
P/E ratio
75.03
52-wk high
CA$12.18
52-wk low
CA$5.66
EPS
CA$0.16
Beta
-0.05
Shares outstanding
98.23M
No. of employees
830
News stories
From web sources and news partners
Profile
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019. Wikipedia
About Knight Therapeutics Inc
CEO-
Employees830
Founded2014
HeadquartersMontreal, Quebec, Canada
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 5, 2026
Fiscal period
Q3 2026
CA$0.05 / CA$0.01
+405.00%beat
Revenue / Est. (CAD)
137.69M / 129.17M
+6.59%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
133.11M
148.44M
144.21M
137.69M
Cost of goods sold
68.38M
79.33M
74.60M
69.26M
Cost of revenue
68.38M
79.33M
74.60M
69.26M
Research and development expenses
9.22M
9.41M
10.56M
9.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35.45M
34.45M
36.64M
38.29M
Operating expense
58.51M
58.53M
60.66M
62.89M
Total operating expenses
126.90M
137.86M
135.25M
132.15M
Operating income
6.21M
10.58M
8.96M
5.54M
Other non operating income
329.00K
4.17M
-487.00K
-213.00K
EBT including unusual items
11.22M
14.18M
-2.10M
-4.86M
EBT excluding unusual items
1.57M
15.50M
7.21M
4.57M
Income tax expense
2.37M
1.01M
1.26M
-2.18M
Effective tax rate
21.12%
7.14%
-59.82%
44.89%
Other operating expenses
-
-
-
-
Net income
8.85M
13.17M
-3.36M
-2.68M
Net profit margin
6.65%
8.87%
-2.33%
-1.95%
Earnings per share
0.10
0.14
-0.03
0.05
Interest and investment income
1.22M
952.00K
901.00K
1.18M
Interest expense
-3.92M
-2.64M
-2.12M
-2.01M
Net interest expenses
-2.70M
-1.69M
-1.22M
-830.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
16.47M
26.77M
23.97M
21.71M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps